Novel microtubule-targeting agents - the epothilones

Biologics: Targets and Therapy

Volumn 2, Issue 4, 2008, Pages 789-811

  Cheng, Kit L ^a   Bradley, Thomas ^a   Budman, Daniel R ^a  

^a North Shore Long Island Center for Advanced Medicine   (United States)

Author keywords

Epothilones; Ixabepilone; Microtubule targeting agents; Taxanes

Indexed keywords

EID: 71249103102     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Abraham J, Agrawal M, Bakke S, et al. 2003. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol, 21:1866-73.
2. Aghajanian C, Burris HA 3rd, Jones S, et al. 2007. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol, 25:1082-8.
3. Ajani JA, Safran H, Bokemeyer C, et al. 2006. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs, 24:441-6.
4. Alexander E, Rosa E, Bolos J, et al. 2008. Sagopilone. Drugs Future, 33:496-505.
5. Altmann K-H. 2005. Recent developments in the chemical biology of epothilones. Current Pharm Design, 11:1595-613.
6. Altmann K-H, Memmert K. 2008. Epothilones as lead structures for new anticancer drugs-pharmacology, fermentation, and structure-activityrelationships. Prog Drug Res, 66:275-334.
7. Altmann KH, Florsheimer A, O'Reilly T, et al. 2004. The natural products epothilones A and B as lead structures for anticancer drug discovery: chemistry, biology, and SAR studies. Prog Med Chem, 42:171-205.
8. Anthony L, Carlisle T, Pommier R, et al. 2003. An open-label phase IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors. Proc Am Soc Clin Oncol, 22:1413a.
9. Awada A, Bleiber H, de Valeriola D, et al. 2001. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol, 20:427a.
10. Beer TM, Higano CS, Saleh M, et al. 2007. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs, 25:565-70.
11. Berrieman HK, Lind MJ, Cawkwell L. 2004. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol, 5:158-64.
12. Beumer JH, Garner RC, Cohen MB, et al. 2007. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs, 25:327-34.
13. Bhat KM and Setaluri V. 2007. Microtubule-associated proteins as targets in cancer chemotherapy. Clin Cancer Res, 13:2849-54.
14. Bijman M, Amerongen G, Laurens N, et al. 2006. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of rac1 and cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther, 5:2348-57.
15. Bollag DM, McQueney PA, Zhu J, et al. 1995. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res, 55:2325-33.
16. Budman DR. 2005. Therapeutic index, tubulin binders, and clinical medicine. Cancer Invest, 23:479-80.
17. Burris H. 2007. In Chemotherapy Foundation Symposium Clinical update on 2nd generation epothilone KOS-158. [online]. URL: www. chemotherapyfoundationsymposium.org.meeting.
18. Burris III H, Awada A, Jones S, et al. 2002. Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol, 21:412a.
19. Burtness B, Goldwasser M, Axelrod R, et al. 2006. A randomized phase II study of BMS-247550 (ixabepilone) given daily ss5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck. Proc Am Soc Clin Oncol, 24:5532a.
20. Calvert P, O'Neill V, Twelves C, et al. 2001. A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol, 20:429a.
21. Casado E, Tabernero J, Melicher B, et al. 2006. Patupilone in chemotherapypretreated patients with advanced colorectal cancer receiving nutritional support and intensive diarrhea management. A phase I multicenter trial. Proc Am Soc Clin Oncol, 24:3593a.
22. Chen JG and Horwitz SB. 2002. Differential mitotic responses to microtubulestabilizing and-destabilizing drugs. Cancer Res, 62:1935-8.
23. Chen T, Molina A, Moore S, et al. 2004. Epothilone B analog (BMS-247550) at the recommended phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. Proc Am Soc Clin Oncol, 22:2115a.
24. Chi K, Beardsley E, Venner P, et al. 2008. A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel. Proc Am Soc Clin Oncol, 26:5166a.
25. Chou TC, Zhang XG, Harris CR, et al. 1998. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci U S A, 95:15798-802.
26. Chuang E, Vahdat L, Caputo T, et al. 2007. Phase I clinical trial of ixabepilone and pegylated liposomal doxorubicin in patients with advanced breast or ovarian cnacers: New York Consortium Trial P7229. Proc Am Soc Clin Oncol, 25:2570a.
27. Conlin A, D'Andrea G, Hudis C, et al. 2008. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiation therapy (WBXRT). Proc Am Soc Clin Oncol, 26:1086a.
28. Cortes J, Baselga J. 2007. Targeting the microtubules in breast cancer beyond taxanes:the epothilones. Oncologist, 12:271-80.
29. Denduluri N, Low JA, Lee JJ, et al. 2007. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol, 25:3421-7.
30. Dreicer R, Li S, Manola J, et al. 2007. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer, 110:759-63.
31. Eng C, Kindler HL, Nattam S, et al. 2004. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol, 15:928-32.
32. Escuin D, Kline ER, Giannakakou P. 2005. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res, 65:9021-8.
33. Esteve MA, Carre M, Braguer D. 2007. Microtubules in apoptosis induction: are they necessary? Curr Cancer Drug Targets, 7:713-29.
34. Faivre S, Delbaldo C, Boige V, et al. 2008. Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies. Eur J Cancer, 44:674-82.
35. Feldman DR, Kondagunta GV, Ginsberg MS, et al. 2007. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. Invest New Drugs, 25:487-90.
36. Feyen F, Cachoux F, Gertsch J, et al. 2008. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res, 41:21-31.
37. Fojo A, Menefee M, Poruchynsky M, et al. 2005. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): Assessment of its activity and demonstration of target engagement in tumor cells. Proc Am Soc Clin Oncol, 23:4541a.
38. Forster M, Kaye S, Oza A, et al. 2007. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res, 13:4178-84.
39. Fumoleau P, Coudert B, Isambert N, et al. 2007. Novel tubulin-targeting agents:anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol, 18(Suppl 5):v9-15.
40. Gadgeel SM, Wozniak A, Boinpally RR, et al. 2005. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res, 11:6233-9.
41. Galsky MD, Small EJ, Oh WK, et al. 2005. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol, 23:1439-46.
42. Gatzemeier U, von Pawel J, Eschbach C, et al. 2007. Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small cell lung cancer. Eur J Cancer Suppl, 5:6548a.
43. Gauler T, Christoph D, Gamarra F, et al. 2008. Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as firstline therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC). Proc Am Soc Clin Oncol, 26:19081a.
44. Gerth K, Bedorf N, Hofle G, et al. 1996. Epohtilons A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiotics, 49:560-3.
45. Giannakakou P, Gussio R, Nogales E, et al. 2000. A common pharmacophore for epothilone and taxanes:molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A, 97:2904-9.
46. Goel S, Cohen M, Comezoglu SN, et al. 2008. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res, 14:2701-9.
47. Goodin S, Kane MP, Rubin EH. 2004. Epothilones:mechanism of action and biologic activity. J Clin Oncol, 22:2015-25.
48. Graff J, Smith D, Neerukonda L, et al. 2008. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol, 26:5141a.
49. Hao D, Hammond L, deBono J, et al. 2002. Continuous weekly administration of the epothilone-B derivative, BMS-247550 (NSC710428): A phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol, 21:411a.
50. Hoffmann J, Vitale I, Buchmann B, et al. 2008. Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res, 68:5301-8.
51. Holen K, Syed S, Hannah A, et al. 2004. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Am Soc Clin Oncol, 22:2024a.
52. Hsin K, Boyer M, Ducreux M, et al. 2006. Efficacy of patupilone in advanced local or metastatic gastric cancer: A phase IIa trial. Proc Am Soc Clin Oncol, 24:4069a.
53. Huang H, Menefee M, Edgerly M, et al. 2008. Ixabepilone (BMS-247550) and metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol, 26:5053a.
54. Hussain A, Dipaola R, Baron A, et al. 2004. A Phase IIa trial of weekly EPO906 in patients with hormone-refractory prostate cancer (HPRC) Proc Am Soc Clin Oncol, 22:4563a.
55. Hussain M, Tangen CM, Lara PN Jr, et al. 2005. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol, 23:8724-9.
56. Jacobs S, Fox B, Krailo M, et al. 2008. Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Proc Am Soc Clin Oncol, 26:10026a.
57. Kamath K, Wilson L, Cabral F, et al. 2005. BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J Biol Chem, 280:12902-7.
58. Khawaja NR, Carre M, Kovacic H, et al. 2008. Patupilone-induced apoptosis is mediated by mitochondrial reactive oxygen species through Bim relocalization to mitochondria. Mol Pharmacol, in press.
59. Klar U, Buchmann B, Schwede W, et al. 2006. Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development. Angew Chem Int, 45:7942-8.
60. Kowalski RJ, Giannakakou P and Hamel E. 1997. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R). J Biol Chem, 272:2534-41.
61. Lechleider R, Kaminskas E, Jiang X, et al. 2008. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous treatments. Clin Cancer Res, 14:4378-84.
62. Lee FY, Borzilleri R, Fairchild CR, et al. 2001. BMS-247550:a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res, 7:1429-37.
63. Lee FY, Borzilleri R, Fairchild CR, et al. 2008. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol, In press.
64. Lee JJ, Swain SM. 2008. The epothilones:translating from the laboratory to the clinic. Clin Cancer Res, 14:1618-24.
65. Lehne G. 2000. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets, 1:85-99.
66. Low JA, Wedam SB, Lee JJ, et al. 2005. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol, 23:2726-34.
67. Magnani M, Ortuso F, Soro S, et al. 2006. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. Febs J, 273:3301-10.
68. Mani S, Huang H, Sundarababu S, et al. 2005. Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res, 11:6359-69.
69. Mani S, McDaid H, Hamilton A, et al. 2004. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res, 10:1289-98.
70. Mani S, McDaid HM, Grossman A, et al. 2007. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol, 18:190-5.
71. Markman M. 2003. Managing taxane toxicities. Support Care Cancer, 11:144-7.
72. Mekhail T, Chung C, Holden S, et al. 2003. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol, 22:515a.
73. Mok TS, Choi E, Yau D, et al. 2006. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology, 71:292-6.
74. Monzo M, Rosell R, Sanchez JJ, et al. 1999. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol, 17:1786-93.
75. Moulder S, Wang M, Gradishar W, et al. 2007. A phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2H) metastatic breast cancer (MBC): A trial coordinated by the Eastern Cooperative Oncology Group (E2103). Proc Am Soc Clin Oncol, 25:152a.
76. Nettles JH, Li H, Cornett B, et al. 2004. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science, 305:866-9. Nicolaou KC, Winssinger N, Pastor J, et al. 1997) Synthesis of epothilones A and B in solid and solution phase. Nature, 387:268-72.
77. Noguchi S. 2006. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci, 97:813-20.
78. O'Brien C, Cavet G, Pandita A, et al. 2008. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res, 68:5380-9.
79. O'Connor O, Straus D, Moskowitz C, et al. 2005. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS247550 induces major and durable remissions in very drug resistant disease. Proc Am Soc Clin Oncol, 23:6569a.
80. Okuno S, Maples WJ, Mahoney MR, et al. 2005. Evaluation of epothilone B analog in advanced soft tissue sarcoma:a phase II study of the phase II consortium. J Clin Oncol, 23:3069-73.
81. Pavlick A, Millward M, Farrell K, et al. 2004. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma (MM). Proc Am Soc Clin Oncol, 22:7542a.
82. Pellegrini F and Budman DR. 2005. Review:tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest, 23:264-73.
83. Perez EA, Lerzo G, Pivot X, et al. 2007. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol, 25:3407-14.
84. Peterson JK, Tucker C, Favours E, et al. 2005. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res, 11:6950-8.
85. Piro L, Rosen L, Parson M, et al. 2003. KOS-862 (epothilone D): A comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol, 22:539a.
86. Poplin E, Moore M, O'Dwyer P, et al. 2003. Safety and efficacy of EPO906 in patients with advanced colorectal cancer: A review of 2 phase II trials. Proc Am Soc Clin Oncol, 22:1135a.
87. Posadas EM, Undevia S, Manchen E, et al. 2007. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biol Ther, 6:490-3.
88. Pusztai L. 2007. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol, 18(Suppl 12):xii15-20.
89. Reese M, Sanchez-Pedregal V, Blommers M, et al. 2006. Pharmacophore mapping by the novel Inpharma method:The epothilone tubulin complex. First European Chemistry Congress. 194a.
90. Reid T, Takimoto C, Verschraegen C, et al. 2008. Evaluation of safety, tolerability and pharmacokinetics (PK) of patupilone in patients with advanced solid tumors and varying degrees of hepatic function: An open-label phase I study. Proc Am Soc Clin Oncol, 26:2557a.
91. Roche H, Yelle L, Cognetti F, et al. 2007. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol, 25:3415-20.
92. Rosenberg JE, Weinberg VK, Kelly WK, et al. 2007. Activity of secondline chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer, 110:556-63.
93. Rubin EH, Rothermel J, Tesfaye F, et al. 2005. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol, 23:9120-9.
94. Sakaushi S, Nishida K, Fukada T, et al. 2008. Differential response of mitotic spindle pole formation to microtubule-stabilizing agents epothilone A and B at low concentrations. Cell Cycle, 7:477-83.
95. Schmid P, Kiewe P, Kuehnhardt D, et al. 2005. A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. Proc Am Soc Clin Oncol, 23:2051a.
96. Sessa C, Perotti A, Llado A, et al. 2007. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol, 18:1548-53.
97. Sessa C, Perotti A, Malossi A, et al. 2003. Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol, 22:519a.
98. Seve P, Mackey J, Isaac S, et al. 2005. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther, 4:2001-7.
99. Seve P, Reiman T, Isaac S, et al. 2008. Protein abundance of class III betatubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site. Anticancer Res, 28:1161-7.
100. Shah R, Kaye S. 2003. In: Handbook of Anticancer Drug Development. Budman, DR, Calvert A, Rowinsky E (eds). Baltimore: Lippincott, Williams and Wilkins. pp. 13-24.
101. Shimizu T, Yamamoto N, Yamada Y, et al. 2008. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol, 61:751-8.
102. Silvani A, Fiumani A, Scaioli V, et al. 2008. A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas. Proc Am Soc Clin Oncol, 26:2083a.
103. Singh D, Taber D, Ansari R, et al. 2006. A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): An updated analysis. Proc Am Soc Clin Oncol, 24:14050a.
104. Smit W, Sufliarsky J, Spanik S, et al. 2005. Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer. Proc Am Soc Clin Oncol, 23:5056a.
105. Smith S, Pro B, van Besien K, et al. 2005. A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphomas. Proc Am Soc Clin Oncol, 23:6625a.
106. Spriggs D, Dupont J, Pezzulli S, et al. 2003. KOS-862 (epothilone D): Phase I dose escalating and pharmacokinetic (PK) study in patients with advanced malignancies. Proc Am Soc Clin Oncol, 22:894a.
107. Spriggs D, Soignet S, Bienvenu B, et al. 2001. Phase 1 first-in-man study of epothilone B analog BMS-247550 in patients with advanced cancer. Proc Am Soc Clin Oncol, 20:428a.
108. Stopeck A, Moulder S, Jones S, et al. 2007. Phase I trial of KOS-1584 (a novel epothilone) using two weekly schedules. Proc Am Soc Clin Oncol, 25:2571a.
109. Stopeck A, Thomas E, Jones S, et al. 2006. Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule. Proc Am Soc Clin Oncol, 24:2041a.
110. Stupp R, Tosoni A, Taal W, et al. 2008. Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma:Initial report of the EORTC study 26061. Proc Am Soc Clin Oncol, 26:2015a.
111. Takimoto C, Fu S, Dhillon N, et al. 2008. Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors:An open-label, phase I study. Proc Am Soc Clin Oncol, 26:2548a.
112. Thomas E. 2008. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol, 26:2223.
113. Thomas E, Tabernero J, Fornier M, et al. 2007a. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol, 25:3399-406.
114. Thomas ES, Gomez HL, Li RK, et al. 2007b. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol, 25:5210-7.
115. Thompson J, Swerdloff J, Escudier B, et al. 2003. Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc Am Soc Clin Oncol, 22:1628a.
116. Vansteenkiste J, Lara PN, Jr. Le Chevalier T, et al. 2007. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non smallcell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol, 25:3448-55.
117. Villalona-Calero M, Goel S, Schaaf L, et al. 2006. First-in-human phase I trial of a novel epothilone, KOS-1584. Proc Am Soc Clin Oncol, 24:2003a.
118. Wenk D, Deconti R, Urbas P, et al. 2008. Phase II trial of sagopilone (ZKEPO), a novel epothilone, in patients with metastatic melanoma. Proc Am Soc Clin Oncol, 26:9046a.
119. Whitehead RP, McCoy S, Rivkin SE, et al. 2006. A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer:a Southwest Oncology Group study. Invest New Drugs, 24:515-20.
120. Wilding G, Chen Y, DiPaola R, et al. 2008. E3803:Updated results on phase II study of a weekly schedule of BMS-247550 for patients with castrate refractory prostate cancer (CRPC). Proc Am Soc Clin Oncol, 26:5070a.
121. Yee L, Lynch T, Villalona-Calero M, et al. 2005. A phase II study of KOS-862 (Epothilone D) as second-line therapy in non-small cell lung cancer Proc Am Soc Clin Oncol, 2005:7127a.
122. Zhuang SH, Agrawal M, Edgerly M, et al. 2005. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer, 103:1932-8.
123. Zhuang SH, Hung YE, Hung L, et al. 2007. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res, 13:7480-6.